Great. I do not disagree with most of it. But it doesn’t change the share count. If Woodford wanted AZN which has gone since then from a a small player to a much larger player in Oncology they could have built up the facility and manufactured the product while sharing profits 50/50. We all would have been better off. Meaning richer.